Fundz
Funding, M&A, exec moves and hiring — matched to your market, with the people to call.See plans →

Oblenio Bio, a Cambridge-based firm focused on autoimmune disease treatments, raises $62M in Series B funding led by Pfizer Ventures to support clinical development of LBL-051.

PRIVATEJun 25, 2026•about 2 months ago

Amount Raised

$62 Million

Round Type

Series B

CambridgeBiotechnologyHealth CareTherapeutics

Investors

Aditum BioGvDeep Track CapitalPfizer Ventures

Description

Oblenio Bio, a company specializing in treating autoimmune diseases, secured $62M in Series B funding. The round was led by Pfizer Ventures, with participation from Deep Track Capital, GV, and Aditum Bio. The funds will be used for the clinical development of LBL-051, a tri-specific T-cell engager. This treatment aims to offer long-term remission for patients with refractory autoimmune diseases.

Company Information

Company

Oblenio Bio

Location

Cambridge, Massachusetts, United States

About

Oblenio Bio is a biotechnology company based in Cambridge, MA, specializing in the treatment of autoimmune diseases. The company is developing LBL-051, a tri-specific T-cell engager intended to induce a broad immune system reset. This innovative therapy aims to address a wide range of refractory autoimmune diseases by safely eliminating problematic B cells and plasma cells. Oblenio Bio's goal is to provide long-term drug-free remission for patients suffering from these debilitating conditions.

Related People

Suggested for you
1 contact
Verified contactsSamantha T., CEO-in-Residence, CEO of Oblenio Bio hidden
Predictive Intelligence
Strategic

ML-powered predictions for Oblenio Bio's next move

Learn about Strategic plan

Funding Insights

Based on industry data
Timeline to next round
Series B companies typically work for 15-20 months before raising new capital
Growth expectations
Series B companies are expected to scale rapidly and expand market reach
VC-backed spending patterns
VC-backed companies spend 89% more on sales and 100% more on marketing than bootstrapped peers
Tech investment trends
83% of B2B companies plan digital investments, with 79% prioritizing customer experience tech

Fundz is a real-time business intelligence platform powered by agentic AI that proactively delivers personalized daily signals — including funding rounds, executive changes, M&A activity, 13F institutional filings, SEC 8-K events, investor activity, and website modifications — based on each user's watchlist and ICP. A trusted data source at firms such as BlackRock, Oracle, Kleiner Perkins, LinkedIn, HubSpot, and Cloudflare, Fundz democratizes the institutional-grade intelligence that previously required a PitchBook or Bloomberg terminal. Features include FundzWatch™ for automated website change detection, Daily Briefing for AI-powered daily briefings, and unified cross-signal alerts across 200,000+ companies. Developers and data teams can access these signals programmatically via the Fundz Funding Data API, with transparent published pricing.